item management s discussion and analysis of financial condition and results of operations the following discussion should be read in conjunction with selected historical financial information item and the consolidated financial statements of conmed which are included elsewhere or incorporated by reference in this form k 
general conmed corporation the company is a medical technology company specializing in instruments and implants for arthroscopic sports medicine  and powered surgical instruments  such as drills and saws  for orthopaedic  ent and neurosurgery 
the company is also a leading developer  manufacturer and supplier of advanced medical devices  including electrosurgical systems  ecg electrodes for heart monitoring  and minimally invasive surgical devices 
the company s products are used in a variety of clinical settings  such as operating rooms  surgery centers  physicians offices and critical care areas of hospitals 
results of operations the following table presents  as a percent of net sales  certain categories included in conmed s consolidated statements of income for the periods indicated years ended december net sales cost of sales gross margin selling and administrative expense research and development expense unusual items income loss from operations interest income expense  net 
income loss before income taxes and extraordinary item provision benefit from income taxes income loss before extraordinary item years ended december and december sales for were  an increase of compared to sales of  in arthroscopy sales grew in to  with of the increase due to internal growth and due to the company s acquisition of an arthroscopy product line from minnesota mining and manufacturing company m in november the arthroscopy acquisition note 
powered surgical instrument sales grew in to  with due to internal growth and due to the company s acquisition of the powered instrument business from m in august the powered instrument acquisition note 
electrosurgery  patient care and other surgical product lines declined in to  approximately of the total sales growth in as compared to reflects the pricing impact of changes in distribution from as compared to the first six months of in connection with the december acquisition of linvatec corporation the linvatec acquisition note from bristol meyers squibb bms  the company entered into fixed price distribution agreements with zimmer  inc  a wholly owned subsidiary of bms  to distribute certain of the company s products in selected geographic markets 
beginning in the third quarter of  most of the products formerly distributed by zimmer were sold and distributed directly by the company  resulting in improved pricing for the affected products 
cost of sales increased to  in compared to  in in connection with the august powered instrument acquisition  the company increased the acquired value of inventory by  this inventory was sold during the quarter ended september and served to increase cost of sales in by  similarly  in connection with purchase accounting for the linvatec acquisition  the company increased the acquired value of inventory by  over its production cost  this inventory was sold during the quarter ended march and served to increase cost of sales in by  excluding the impact of these non recurring adjustments  cost of sales increased to  in from  in  as a result of increased sales volumes as described above 
excluding the nonrecurring adjustments  the company s gross margin percentage for was compared to for the increase in gross margin percentage is primarily attributable to higher sales volumes in the company s orthopaedic product lines which carry higher gross margins than certain of the company s other product lines as well as improved pricing resulting from the elimination of most of the fixed price product distribution agreements with zimmer discussed previously 
selling and administrative costs increased to  in as compared to  in the increase in selling and administrative expense is primarily a result of additional selling expense associated with the increase in sales in as compared to  including increased costs associated with the direct selling and distribution of products formerly distributed through zimmer during the first half of and increased intangible amortization resulting from the powered instrument acquisition and the arthroscopy acquisition 
partially offsetting these increases  during the fourth quarter of  the company recognized the benefit amounting to  of a previously recorded litigation accrual which was settled on favorable terms and is included in selling and administrative expense 
as a result of these costs  as a percentage of sales  selling and administrative expense increased to in as compared to in research and development expense was  in as compared to  in as a percentage of sales  research and development expense was in as compared to in the amount of research and development expense incurred in is consistent with representing the company s ongoing efforts in this area 
interest expense for was  compared to  in in connection with the powered instrument acquisition  the company s existing credit facility was amended in the third quarter of to provide for an additional  loan commitment which was used to fund the acquisition purchase price 
the increase in interest expense is a result of these higher term loan borrowings and higher average borrowings under the company s revolving credit facility during as compared to the company funded its arthroscopy acquisition during the fourth quarter of through borrowings under the revolving credit facility which resulted in the higher average borrowings 
offsetting the interest on these increased borrowings was reduced interest expense on the company s term loans as a result of scheduled quarterly principal payments totaling  in see discussion under liquidity and capital resources section of management s discussion and analysis of financial condition and results of operations 
during the first quarter of  the company completed an offering of subordinated notes the notes and used the net proceeds to repay a portion of the company s term loans under its credit facility 
deferred financing fees relating to the portion of the credit facility repaid amounting to   net of income taxes were written off as an extraordinary charge 
see note and discussion under liquidity and capital resources section of management s discussion and analysis of financial condition and results of operations 
years ended december and december sales for were  an increase of compared to sales of  in approximately of the total sales increase is related to the linvatec acquisition 
the remaining increase of approximately is attributable to the july surgical suction instrument and tubing acquisition from davol  inc the davol acquisition note 
cost of sales increased to  in compared to  in in connection with purchase accounting for the linvatec acquisition  the company increased the acquired value of inventory by  over its production cost  this inventory was sold during the quarter ended march and served to increase cost of sales in by  excluding the impact of this non recurring adjustment  cost of sales increased to  in from  in  as a result of increased sales volumes as described above 
excluding the nonrecurring adjustment  the company s gross margin percentage for was compared to for the increase in gross margin percentage is primarily attributable to sales of the company s orthopaedic product lines acquired through the linvatec acquisition which carry higher gross margins than certain of the company s other product lines 
additionally as discussed above  in connection with the linvatec acquisition  the company entered into fixed price distribution agreements with zimmer to distribute certain of the company s products in selected geographic markets 
beginning in the third quarter of  most of the products formerly distributed by zimmer were sold and distributed directly by the company 
as a result  the company s gross margin percentage was in the second half of as compared to in the first half of selling and administrative costs increased to  in as compared to  in  primarily as a result of the linvatec acquisition 
as a percentage of sales  selling and administrative expense was in and in this increase reflects the overall higher selling and administrative efforts associated with the sales of the orthopaedic products acquired in connection with the linvatec acquisition 
research and development expense was  in as compared to  in the increase reflects expense related to linvatec research and development activities 
there were no unusual charges recorded in as discussed in note  in conmed recorded  of unusual items  including a  non cash acquisition charge for the write off of the in process research and development comprised of products in the development stage acquired in the linvatec acquisition   of deferred financing fees resulting from the refinancing of the company s loan agreements in connection with the linvatec acquisition and a  charge for the closing of conmed s dayton  ohio manufacturing facility 
interest expense for was  compared to interest income of  in as discussed under liquidity and capital resources section of management s discussion and analysis of financial condition and results of operations  the company acquired linvatec corporation on december  and borrowed million under its credit facility 
the company had no borrowings outstanding during  except the acquisition related borrowings on december  the company completed an offering of subordinated notes during the quarter ended march and used the net proceeds to repay a portion of the company s term loans under its credit facility 
deferred financing fees relating to the portion of the credit facility repaid amounting to   net of income taxes were written off as an extraordinary item in liquidity and capital resources the company s net working capital position increased  or to  at december compared to  at december net cash provided by operations was  for compared to  for operating cash flow was positively impacted by higher net income  depreciation  and amortization in as compared to  as well as the change in deferred income taxes 
negatively impacting operating cash flow in were increases in accounts receivable and inventory and decreases in accounts payable  accrued interest and accrued liabilities 
the increase in accounts receivable is primarily related to the increase in sales  the increase in inventory is related to the arthroscopy acquisition and powered instrument acquisition and overall higher levels of inventory on hand 
the decreases in accounts payable  accrued interest and accrued liabilities are primarily related to the timing of the payment of these liabilities 
adversely impacting operating cash flows in as compared to was an increase in accounts receivable and inventories primarily as a result of the timing of the company s assumption of linvatec s international operations previously managed by zimmer 
in connection with the linvatec acquisition  the company assumed responsibility for the majority of linvatec s international operations on july  accordingly  the receivables and inventory of the international operations were not acquired or funded by the company until the second half of net cash used by investing activities in included  paid related to the powered instrument acquisition 
net cash used by investing activities in included  paid related to the arthroscopy acquisition and  of payments related to the linvatec and davol acquisitions 
components of the linvatec acquisition related payments include investment banking and professional fees related to the acquisition  payments associated with the closure of linvatec s san dimas  california facility  payments to zimmer  inc to acquire demonstration equipment  and other acquisition related payments 
cash payments related to the davol acquisition amounted to  of which  represented severance costs associated with closure of the company s kansas manufacturing operation 
net cash used by investing activities in includes  in payments related to the linvatec acquisition and  related to the davol acquisition 
capital expenditures for  and amounted to   and  respectively 
financing activities during consisted primarily of a  term loan used to fund the powered instrument acquisition  scheduled payments of  on the company s previously existing term loans and  in repayments on the company s revolving credit facility 
financing activities during involved the completion of the notes offering in the aggregate principal amount of  net proceeds from the offering amounting to  were used to repay a portion of the company s term loans under its credit facility 
additionally  the company borrowed  under the revolving credit facility primarily to finance the arthroscopy acquisition and made scheduled payments of  on the company s term loans 
financing activities during involved borrowing  in term loans and  on the revolving credit facility to finance the linvatec acquisition 
management believes that cash generated from operations  its current cash resources and funds available under its revolving credit facility will provide sufficient liquidity to ensure continued working capital for operations  debt service and funding of capital expenditures in the foreseeable future 
foreign operations the company s foreign operations are subject to special risks inherent in doing business outside the united states  including governmental instability  war and other international conflicts  civil and labor disturbances  requirements of local ownership  partial or total expropriation  nationalization  currency devaluation  foreign exchange controls and foreign laws and policies  each of which may limit the movement of assets or funds or result in the deprivation of contract rights or the taking of property without fair compensation 
item a 
quantitative and qualitative disclosures about market risk the company s principal market risks involve foreign currency exchange rates and interest rates 
the company manufactures its products in the united states and distributes its products throughout the world 
as a result  the company s financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets 
as of december   the company had not established a foreign currency hedging program 
the company has mitigated and will continue to mitigate its foreign currency exposure by transacting the majority of its foreign sales in united states dollars 
to date  changes in foreign currency exchange rates have not had a material effect on the company s financial conditions or results of operations 
the company will continue to monitor and evaluate its foreign currency exposure and the need to establish a foreign currency hedging program 
the company s exposure to market risk for changes in interest rates relate to its borrowings 
the company does not use derivative financial instruments for trading or other speculative purposes 
interest rate swaps  a form of derivative  are used to manage interest rate risk 
currently  the company has entered into two interest rate swaps expiring in june which convert  of the approximate  of floating rate borrowings under the company s credit facility into fixed rate borrowings at rates ranging from to 
provisions in one of the interest rate swaps cancels such agreement when libor exceeds 
if market interest rates for similar borrowings average more in than they did in  the company s interest expense  after considering the effects of its interest rate swaps  would increase  and income before taxes would decrease by  comparatively  if market interest rates averaged less in than they did during  the company s interest expense  after considering the effects of its interest rate swaps  would decrease  and income before taxes would increase by  these amounts are determined by considering the impact of hypothetical interest rates on the company s borrowing cost and interest rate swap agreements and does not consider any actions by management to mitigate its exposure to such a change 

